Fintel reports that on January 23, 2025, Piper Sandler initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener An announcement ...

Bright Minds Biosciences (DRUG) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi.Invest with Confidence: ...

Piper Sandler initiated coverage of Bright Minds Biosciences (DRUG) with an Overweight rating and $93 price target The firm believes the ...

Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Bright Minds Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Donald Trump and biotech stocks joined the top 10. Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new ...

Fintel reports that on January 10, 2025, HC Wainwright & Co. initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a Buy recommendation. As of March 27, 2023, the average one-year ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31 ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...